Maxim Group initiated coverage of scPharmaceuticals (NASDQ:SCPH) with a “buy” rating and price target of $10. The stock closed at $4.89 on Aug. 2. scPharmaceuticals is a late-stage pre-commercial company developing...
Cantor Fitzgerald initiated coverage of Clever Leaves Holdings (NASDAQ:CLVR) with an “overweight” rating and $4.50 price target. The stock closed at 92 cents on July 27. “In relative terms, the stock offers better ‘pure...
Tonix Pharmaceuticals (NASDAQ:TNXP) is collaborating with the Kenya Medical Research Institute to plan, seek regulatory approval for and conduct a Phase 1 clinical study in Kenya to develop Tonix’s TNX-801 as a vaccine...
Cantor Fitzgerald downgraded ObsEva (NASDAQ:OBSV) to “neutral” from “overweight” and slashed its price target to $1 from $6 after the company announced a corporate restructuring and refocus of its development and...
BTIG launched coverage of Keros Therapeutics (NASDAQ:KROS) with a “buy” rating and $80 price target. The stock closed at $28.53 on July 25. Analyst Julian Harrison writes that following Acceleron’s impressive foray into...
Maxim Group upgraded Agile Therapeutics (NASDAQ:AGRX) to “buy” from “hold” and set a $1 price target, after the company closed a recent equity offering, enacted austerity measures and refined its commercial efforts. The...
Ladenburg Thalmann initiated coverage of Liquidia (NASDAQ:LQDA) with a “buy” rating and $15 price target. The stock closed at $5.03 on July 21. Liquidia is a commercial-stage biotechnology company currently focused on...
Cantor Fitzgerald launched coverage of BioVie (NASDAQ:BIVI) with an “overweight” rating and $7 price target. The stock closed at $2.10 on July 21. BioVie is developing NE3107, an orally bioavailable anti-inflammatory...
Dawson James downgraded ProPhase Labs (NASDAQ:PRPH) to “sell” from “neutral” with a price target of $5 after the company announced a license agreement with Global BioLife. Shares of ProPhase were quoted at $11.71, down...
SVB Securities initiated coverage of Pliant Therapeutics (NASDAQ:PLRX) with an “outperform” rating and price target of $33. The stock closed at $19.22 on July 19. Pliant is a clinical-stage biopharmaceutical company...